Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.
Open Orphan plc has changed its name to hVIVO plc (Ticker: HVO)
Watch hVIVO’s Capital Markets Day 2022 presentation here.
We are a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, providing end-to-end early clinical development services for its broad and longstanding client base of biopharma companies
Yamin 'Mo' Khan
CEO at hVIVO
"The first half of 2023 has delivered another period of excellent growth and progress towards our goal of establishing a long-term sustainable growth model. The increasing number of trials, as well as the growing volunteer cohorts and expanding use cases, highlights that the human challenge market is experiencing a strong growth trend that we strongly believe will continue over the long term. The outlook for the business is extremely positive, as our new state-of-the-art facility sets us up to accelerate our growth over the long term. We are delighted to increase our revenue guidance and EBITDA margin guidance for 2023. Finally, I would like to thank our staff for their continued dedication and boundless enthusiasm as we progress towards our vision to transform global healthcare."
H1 23 Revenue
H1 23 EBITDA Margin
Cash 30 June 2023
2023 Revenue Target (exluding other income)
Strong market dynamics
Scalable infrastructure
Trusted Partner
Orderbook growth
Our values
We are a diverse group of individuals working for one team to achieve common goals. Each one of us plays a crucial role in the team's success. We are committed to each other and the team. We learn from our failures together and celebrate our successes together. Diversity and inclusion are at the core of our organisation, and we consider our clients’ success as our own.
We are dedicated to the growth of our colleagues, customers and shareholders. We are committed to our personal growth and the development of our colleagues. We aim to grow our client base and the value of their products. We will repay the trust of our shareholders in achieving greater returns on their investment. We will achieve this by creating a culture of intellectual freedom across the organisation.
We take personal ownership of our actions and always act in ways that builds trust and respect with all our stakeholders. We pride ourselves in maintaining the welfare and the rights of all individuals and ensuring the best outcomes for our volunteers and patients. We are honest, have strong moral and ethical principles and are reliable and consistent in our delivery.
We are pioneering in our approach, always curious. We use our unique scientific expertise to guide our client’s towards successful outcomes. We embrace new opportunities and rise to new challenges. Our agility allows us to redefine our markets and be highly responsive to our clients’ requirements.